Ryohei Katayama
YOU?
Author Swipe
View article: Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study
Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study Open
View article: Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma
Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma Open
Glioblastoma (GBM) remains one of the most aggressive and challenging brain tumors. Unfortunately, current clinical treatment options offer limited efficacy, highlighting the necessity for uncovering novel therapeutic strategies. Here, mon…
View article: Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra‐Terminal Domain Inhibitors
Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra‐Terminal Domain Inhibitors Open
Osimertinib, a third‐generation EGFR‐tyrosine kinase inhibitor, is the first‐line therapy for lung cancer harboring EGFR mutations. The mechanisms underlying osimertinib resistance are diverse, with approximately half remaining unknown. Ep…
View article: AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts
AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts Open
Anaplastic lymphoma kinase (ALK) rearranged non‐small cell lung cancer (NSCLC) shows marked tumor shrinkage by ALK‐tyrosine kinase inhibitors (TKIs). However, tumors almost inevitably relapse owing to the development of acquired resistance…
View article: Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization Open
View article: Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma Open
Osteosarcoma (OS) is a primary malignant bone tumor primarily affecting children and adolescents. The lack of progress in drug development for OS is partly due to unidentified actionable oncogenic drivers common to OS. In this study, we de…
View article: Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer Open
View article: Combined blockade of <scp>GPX4</scp> and activated <scp>EGFR</scp>/<scp>HER3</scp> bypass pathways inhibits the development of <scp>ALK</scp>‐inhibitor‐induced tolerant persister cells in <scp><i>ALK</i></scp>‐fusion‐positive lung cancer
Combined blockade of <span>GPX4</span> and activated <span>EGFR</span>/<span>HER3</span> bypass pathways inhibits the development of <span>ALK</span>‐inhibitor‐induced tolerant persister cells in <span><i>ALK</i></span>‐fusion‐positive lung cancer Open
Cancers can develop resistance to treatment with ALK tyrosine kinase inhibitors (ALK‐TKIs) via emergence of a subpopulation of drug‐tolerant persister (DTP) cells that can survive initial drug treatment long enough to acquire genetic aberr…
View article: Identification of <i>C</i>-mannosylation in a receptor tyrosine kinase AXL
Identification of <i>C</i>-mannosylation in a receptor tyrosine kinase AXL Open
C-mannosylation is a unique type of glycosylation in which a mannose is added to tryptophan in a protein. However, the biological function of C-mannosylation is still largely unknown. AXL is a receptor tyrosine kinase, and its overexpressi…
View article: descSPIM: an affordable and easy-to-build light-sheet microscope optimized for tissue clearing techniques
descSPIM: an affordable and easy-to-build light-sheet microscope optimized for tissue clearing techniques Open
View article: A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer Open
Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge. Here, we first demonstrated the bindi…
View article: NuclSeg: nuclei segmentation using semi-supervised stain deconvolution
NuclSeg: nuclei segmentation using semi-supervised stain deconvolution Open
Recently, deep learning-inferred stain deconvolution/separation-based nuclei segmentation works demonstrated significant results by translating low-cost and prevalent immunohistochemical (IHC) slides to more expensive-yet-informative multi…
View article: APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells Open
View article: MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF Open
Although tyrosine kinase inhibitor (TKI) therapy shows marked clinical efficacy in patients with anaplastic lymphoma kinase-positive (ALK+) and ROS proto-oncogene 1-positive (ROS1+) non-small cell lung cancer (NSCLC), most of these patient…
View article: Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancer
Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancer Open
Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lympho…
View article: Ultra‐Rapid and Specific Gelation of Collagen Molecules for Transparent and Tough Gels by Transition Metal Complexation
Ultra‐Rapid and Specific Gelation of Collagen Molecules for Transparent and Tough Gels by Transition Metal Complexation Open
Collagen is the most abundant protein in the human body and one of the main components of stromal tissues in tumors which have a high elastic modulus of over 50 kPa. Although collagen has been widely used as a cell culture scaffold for can…
View article: Brigatinib in Japanese patients with <i>ALK</i>‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
Brigatinib in Japanese patients with <i>ALK</i>‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial Open
The phase 2, single‐arm, multicenter, open‐label J‐ALTA study evaluated the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non‐small‐cell lung cancer (NSCLC). One expansion cohort of J‐ALTA enrolled patients prev…
View article: Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer
Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer Open
View article: Data from The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Data from The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer Open
Non–small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluati…
View article: Supplementary Movie 4 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Supplementary Movie 4 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance Open
Control (SK-MEL-28 Fucci).
View article: Data from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i>-Rearranged Lung Cancer
Data from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i>-Rearranged Lung Cancer Open
Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progress…
View article: Supplementary Movie 1 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Supplementary Movie 1 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance Open
Control (EBC1-Fucci).
View article: Data from Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Data from Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers Open
Neurotrophic receptor tyrosine kinase 1 (NTRK1) gene rearrangement leads to constitutive activation of NTRK1, which induces high-transforming ability. NTRK-rearranged cancers have been identified in several cancer types, such…
View article: Supplementary Table S1 from <i>APC</i> Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Supplementary Table S1 from <i>APC</i> Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer Open
IC50 values of colorectal cancer cell lines and colorectal cancer patient-derived cells
View article: Supplementary Figures 1-4 from The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Supplementary Figures 1-4 from The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer Open
PDF file 135K, Figure S1 contains data about Ceritinib specificity and potency on crizotinib na?ve EML4-ALK wild-type cells. Figure S2 contains the Cell survival curves of H3122 CR1, MGH021-4 and MGH045 cells following treatment with Crizo…
View article: Data from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Data from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance Open
Tivantinib (ARQ197) was first reported as a highly selective inhibitor of c-MET and is currently being investigated in a phase III clinical trial. However, as recently reported by us and another group, tivantinib showed cytotoxic activity …
View article: Supplementary Movie 5 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Supplementary Movie 5 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance Open
Tivantinib treated (SK-MEL-28 Fucci).
View article: Supplementary Movie 1 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Supplementary Movie 1 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance Open
Control (EBC1-Fucci).
View article: Supplementary Figures S1-S11 and Table from Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Supplementary Figures S1-S11 and Table from Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers Open
Supplementary FigureS1： Sensitivity of TPM3â€�NTRK1 Ba/F3 clones to various NTRK1 inhibitors; Supplementary FigureS2： Sensitivity of TPM3â€�NTRK1 G595R mutant Ba/F3 cells to various NTRK1 inhibitors; Supplementary Figure S3： Sensitiv…
View article: Supplementary Movie 2 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Supplementary Movie 2 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance Open
Tivantinib treated (EBC1-Fucci).